shutterstock_436456039
News
Antibody-drug conjugate receives US FDA Breakthrough Therapy Designation in late-line relapsed or refractory osteosarcoma
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for GSK's GSK5764227 (GSK’227), its B7-H3-targeted antibody-drug conjugate (ADC) being evaluated for...
Araris enters collaboration with Chugai to develop next-generation ADCs
Araris, a Swiss oncology biotech company developing next-generation antibody drug conjugates (ADCs), has entered a Research Collaboration and Option to License Agreement (RCO) under...
TEPOXX approved in Japan for treatment of orthopoxviruses
SIGA Technologies' antiviral treatment TEPOXX (tecovirimat 200 mg capsules), marketed as TPOXX in the United States, has received regulatory approval in Japan for the...
